Compare MPB & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | CMPX |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.0M | 927.5M |
| IPO Year | 1996 | 2020 |
| Metric | MPB | CMPX |
|---|---|---|
| Price | $32.35 | $2.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $37.00 | $14.57 |
| AVG Volume (30 Days) | 106.5K | ★ 12.1M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | $934.41 |
| P/E Ratio | $90.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.83 | $1.61 |
| 52 Week High | $35.22 | $6.88 |
| Indicator | MPB | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 34.36 |
| Support Level | $30.66 | $1.61 |
| Resistance Level | $34.88 | $3.54 |
| Average True Range (ATR) | 0.80 | 0.14 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 50.90 | 78.75 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.